A compliant aortic model for in vitro simulations: Design and manufacturing process

We design and manufacture a silicone model of the human aorta, able to mimic both the geometrical and the mechanical properties of physiological individuals, with a specific focus on reproducing the compliance. In fact, while the models available in the literature exhibit an unrealistic compliant behavior, though they are detailed from the geometrical viewpoint, here the goal is to provide an accurate compliant tool for in vitro testing the devices that interface with the vascular system. A parametric design of the aortic model is obtained based on the available literature data, and the model is manufactured with a specific silicone mixture using rapid prototyping and molding techniques. The manufactured prototype has been tested by means of computed tomography scans for evaluating the matching of the mechanical properties with the desired ones. Results show a high degree of adherence between the imposed and the measured compliance values for each main aortic section. Thus, our work proves the feasibility of the approach, and the possibility to manufacture compliant models that reproduce the mechanical behavior of the aorta for in vitro studies

Predicting aortic enlargement in type B aortic dissection

Patients with uncomplicated acute type B aortic dissection (ABAD) can generally be treated with conservative medical management. However, these patients may develop aortic enlargement during follow-up, with the risk of rupture. Several predictors have been studied in recent years to identify ABAD patients at high risk of aortic enlargement, who may benefit from early surgical or endovascular intervention. This study reviewed and summarized the current available literature on prognostic variables related to aortic enlargement during follow-up in uncomplicated ABAD patients. It revealed multiple factors affecting aortic expansion including demographic, clinical, pharmacologic and radiologic variables. Such predictors may be used to identify those ABAD patients at higher risk for aortic enlargement who may benefit from closer radiologic surveillance or early endovascular intervention. This approach deserves even more consideration because a significant number of patients develop aneurysmal degeneration along the dissected segments during follow-up, and may lose the opportunity for endovascular treatment if not identified at an early stage

Time course development of insulin resistance, adipose and liver inflammation.

<p>Mice were maintained on a high-fat diet (HFD) 0, 6, 12 and 24 weeks prior to clamp experiment to induce insulin resistance. (A) shows HFD-induced decrease in glucose infusion rate (GIR) under hyperinsulinemic conditions, indicating development of whole body insulin resistance. (B) HFD feeding resulted in a gradual decrease of tissue-specific uptake of glucose into white adipose tissue (WAT). (C) HFD feeding increased hepatic glucose production after 24 weeks of HFD, indicating development of hepatic insulin resistance. ‘Basal’ indicates prior to hyperinsulinemic clamp conditions and ‘clamp’ indicates hyperinsulinemic clamp conditions. (D) Representative microphotographs of HPS-stained WAT cross-sections, showing WAT inflammation (i.e. crown-like structures) already after 6 weeks of HFD feeding. (E) Representative microphotographs of HE-stained liver cross-sections, showing NASH development after 24 weeks of HFD feeding (arrow heads indicate clusters of inflammatory cells). (F) Quantitative analysis of crown-likes structures (CLS), demonstrating gradual development of WAT inflammation by HFD feeding. (G) Hepatic inflammation (number of inflammatory cell aggregates per 100x field) was induced after 24 weeks of HFD feeding. All data are mean±SEM, n = 7-11/group. * <i>p<</i>0.05 ** <i>p<</i>0.01 *** <i>p<</i>0.001 compared with t = 0. # <i>p<</i>0.05, ###<i>p<</i>0.01 compared to week 24.</p

Biomechanical Changes After Thoracic Endovascular Aortic Repair in Type B Dissection : A Systematic Review

Thoracic endovascular aortic repair (TEVAR) has evolved into an established treatment option for type B aortic dissection (TBAD) since it was first introduced 2 decades ago. Morbidity and mortality have decreased due to the minimally invasive character of TEVAR, with adequate stabilization of the dissection, restoration of true lumen perfusion, and subsequent positive aortic remodeling. However, several studies have reported severe setbacks of this technique. Indeed, little is known about the biomechanical behavior of implanted thoracic stent-grafts and the impact on the vascular system. This study sought to systematically review the performance and behavior of implanted thoracic stent-grafts and related biomechanical aortic changes in TBAD patients in order to update current knowledge and future perspectives

Contemporary Management Strategies for Chronic Type B Aortic Dissections: A Systematic Review

<div><p>Background</p><p>Currently, the optimal management strategy for chronic type B aortic dissections (CBAD) is unknown. Therefore, we systematically reviewed the literature to compare results of open surgical repair (OSR), standard thoracic endovascular aortic repair (TEVAR) or branched and fenestrated TEVAR (BEVAR/FEVAR) for CBAD.</p><p>Methods</p><p>EMBASE and MEDLINE databases were searched for eligible studies between January 2000 and October 2015. Studies describing outcomes of OSR, TEVAR, B/FEVAR, or all, for CBAD patients initially treated with medical therapy, were included. Primary endpoints were early mortality, and one-year and five-year survival. Secondary endpoints included occurrence of complications. Furthermore, a Time until Treatment Equipoise (TUTE) graph was constructed.</p><p>Results</p><p>Thirty-five articles were selected for systematic review. A total of 1081 OSR patients, 1397 TEVAR patients and 61 B/FEVAR patients were identified. Early mortality ranged from 5.6% to 21.0% for OSR, 0.0% to 13.7% for TEVAR, and 0.0% to 9.7% for B/FEVAR. For OSR, one-year and five-year survival ranged 72.0%-92.0% and 53.0%-86.7%, respectively. For TEVAR, one-year survival was 82.9%-100.0% and five-year survival 70.0%-88.9%. For B/FEVAR only one-year survival was available, ranging between 76.4% and 100.0%. Most common postoperative complications included stroke (OSR 0.0%-13.3%, TEVAR 0.0%-11.8%), spinal cord ischemia (OSR 0.0%-16.4%, TEVAR 0.0%-12.5%, B/FEVAR 0.0%-12.9%) and acute renal failure (OSR 0.0%-33.3%, TEVAR 0.0%-34.4%, B/FEVAR 0.0%-3.2%). Most common long-term complications after OSR included aneurysm formation (5.8%-20.0%) and new type A dissection (1.7–2.2%). Early complications after TEVAR included retrograde dissection (0.0%-7.1%), malperfusion (1.3%–9.4%), cardiac complications (0.0%–5.9%) and rupture (0.5%–5.0%). Most common long-term complications after TEVAR were rupture (0.5%–7.1%), endoleaks (0.0%–15.8%) and cardiac complications (5.9%-7.1%). No short-term aortic rupture or malperfusion was observed after B/FEVAR. Long-term complications included malperfusion (6.5%) and endoleaks (0.0%-66.7%). Reintervention rates after OSR, TEVAR and B/FEVAR were 5.8%-29.0%, 4.3%-47.4% and 0.0%-53.3%, respectively. TUTE for OSR was 2.7 years, for TEVAR 9.9 months and for B/FEVAR 10.3 months.</p><p>Conclusion</p><p>We found a limited early survival benefit of standard TEVAR over OSR for CBAD. Complication rates after TEVAR are higher, but complications after OSR are usually more serious. Initial experiences with B/FEVAR show its feasibility, but long-term results are needed to compare it to OSR and standard TEVAR. We conclude that optimal treatment of CBAD remains debatable and merits a patient specific decision. TUTE seems a feasible and useful tool to better understand management outcomes of CBAD.</p></div

Complications and survival OSR.

<p>Complications and survival OSR.</p

Time until Treatment Equipoise.

<p><b>Results of TUTE analysis</b> for OSR (top), TEVAR (middle) and B/FEVAR (bottom) for CBAD.</p

Complications and survival TEVAR.

<p>Complications and survival TEVAR.</p